Board of Directors
Keld Fosgerau (interim chair)
Keld Fosgerau is a drug development professional with >25 years of international experience in leading companies, functions, departments and projects in virtual start-ups, established biotech, CROs, and in large integrated pharmaceutical organizations from novel target discovery to early clinical development. Keld Fosgerau delivered on 8 clinical candidates as a leader especially in the field of peptide therapeutics. Keld Fosgerau obtained has a MSc in chemistry (1995), a PhD in medicine from Copenhagen University (2000), and a bachelor MBA from Copenhagen Business School (2010). Keld previously held senior management positions as SVP of Research at Zealand Pharma, VP at Novo Nordisk, and CSO at Gubra and Keld Fosgerau has published more than 14 patent applications, 75 abstracts/proceedings, and 25 publications with more than 3000 citations. Keld founded Pephexia Therapeutics in 2020.
Professor, MBA, DSc, DM
Andrew Coats has over 30 years of experience as an academic manager, having been both Dean of Medicine and Deputy Vice-Chancellor at the University of Sydney and head of Clinical Cardiology at Imperial College and the Royal Brompton Hospital in London. Andrew also served as CEO of the Norwich Research Park in the UK. Andrew is an experienced board director and chairman with an MBA from London Business School. He has over 20 years of experience of company boards in roles including audit, remuneration, nominations and governance committees in biotechnology, publishing health care and education, including the George Institute of International Health, the Woolcock Institute, Lone Star Heart, Myotec, PsiOxus, Radcliffe Group, ESN Cleer and Faraday (Australia). Andrew has been on the board of the Heart Failure Association (HFA) of the ESC since 2012 and will be its President from 2020 to 2022. He has been a member of over 20 international clinical trial steering committees in the fields of heart failure and cachexia and has over 750 career research papers, 100,000 citations and an h-Index of 135. Andrew Coats is a co-founder of Actimed Therapeutics, having previously founded Myotec (later renamed PsiOxus Therapeutics).
CFO at Northsea Therapeutics
Mats Blom holds a position as CFO at North Sea Therapeutics in Amsterdam. Mats has extensive managerial experience and has held CFO positions in several public and non-public companies. He has served as CFO of Zealand Pharma A/B, a biotechnology company dual listed at Nasdaq in New York and Copenhagen and Swedish Orphan International, an orphan drug company acquired by BioVitrum in 2009. In addition, Mats has been CFO at Modus Therapeutics, Active Biotech AB and Anoto Group AB. He has also served as a management consultant at Gemini Consulting and Ernst & Young. Mats holds a BA in Business Administration and Economics from the University of Lund and an MBA from IESE University of Navarra, Barcelona. Mats is currently board member of Hansa Biopharma and Auris Medical.
MSc, eMBA. ass. partner at MEdEdGS
Yann Colardelle is a professional in communications and medical education who has been involved in research and education in cachexia for more than 15 years. In 1998 he founded Medical Education Global Solutions, a leading independent medical education company with a focus on global and multidisciplinary projects. Yann holds a degree from the University of Provence and an eMBA at Paris Dauphine. Yann Colardelle is a co-founder of Actimed Therapeutics.
Management and advisors
Keld Fosgerau is a broad drug development professional with >25 years of international experience in leading companies, functions, departments and projects in virtual start-ups, established biotech, CROs, and in large integrated pharmaceutical organizations from novel target discovery to early clinical development. Keld Fosgerau delivered on 8 clinical candidates as a leader especially in the field of peptide therapeutics. Keld Fosgerau obtained has a MSc in chemistry (1995), a PhD in medicine from Copenhagen University (2000), and a bachelor MBA from Copenhagen Business School (2010). Keld previously held senior management positions as SVP of Research at Zealand Pharma A/S, VP at Novo Nordisk A/S, and CSO at Gubra ApS and Keld Fosgerau has published more than 14 patent applications, 75 abstracts/proceedings, and 25 publications with more than 3000 citations. Keld founded Pephexia Therapeutics in 2020.
Søren Ljungberg Pedersen
PhD, CTO & Head of Research
Søren Ljungberg Pedersen is a peptide drug hunter professional with >15 years of drug development experience from biotech as leader, peptide drug discovery specialist and pre-clinical discovery advisor. Søren Ljungberg Pedersen has profound experience from several successful international collaborations with large pharmaceutical companies. He obtained a MSc in Pharmaceutical Chemistry in 2005 and a PhD in Bioorganic chemistry in 2009. Following several Post-Doc positions, Søren held positions as Chemist at Novo Nordisk A/S and Senior Scientist, Group Leader Chemistry & IP, Group Leader Pharmaceutical Research at Gubra Aps. Søren Ljungberg Pedersen has published several patent applications, numerous abstracts and proceedings, a peptide synthesis book, and >30 scientific publications.
Corporate attorney, advisor
Kristopher Brown is a partner in the Life Sciences and Technology group at Goodwin Procter LLP. Kris focuses his practice on capital markets, M&A, collaboration and licensing arrangements, private equity and venture capital financing transactions. He represents numerous financial and corporate strategic investors as well as many established and emerging growth companies in the life sciences, technology and healthtech sectors. Kris is also an active global angel investor and has been among the first investors in over 50 startups.
Dr. Anders Hinsby
Anders Hinsby has more than 15 years of experience as a biotech entrepreneur, executive and investor. Currently, he is the CEO of Muna Therapeutics and works as entrepreneur-in-residence with Novo Seeds/Biorigin. He co-founded and was the CEO of Orphazyme A/S from 2009 to 2019 and led the company’s journey from University spin-out to a late-stage biopharmaceuticals company with a focus on rare diseases. In 2017 he led Orphazyme’s IPO on NASDAQ Copenhagen raising 90 MUSD. Prior to Orphazyme he was a Principal and later Partner in BankInvest Biomedical Venture, a Danish life-science dedicated venture capital fund. He currently serves on the Boards of Intomics A/S a Danish Biotech. Anders has a Ph.D. in Medicine from the University of Copenhagen.
Dr. Kristian Strømgaard (advisor)
Professor, PhD, advisor
Kristian Strømgaard obtained an MSc degree in Chemical Research from University College London, a PhD degree in medicinal chemistry (1999) and subsequently did a post doc at Columbia University. In 2006, he was appointed full professor at the age of 36. In 2012, he co-founded Avilex Pharma, and brought the lead compound into clinical development. In 2014, he was appointed Director of Center for Biopharmaceuticals, a research center on peptide and protein engineering. Recently, he spent a year as visiting professor at Harvard Medical School. Kristian Strømgaard is the co-founder of Avilex Pharma (2012), a spinout company exploring protein-protein interactions as novel disease targets. Winner of ‘The Copenhagen Spin-out Award for most promising company’, 2013. Obtained >DKK 55 mio. in funds from Novo Seeds, Grand Solutions, Wellcome Trust, Growth Fund DK and Innobooster.
Communication expert, advisor
Per Toftager has been working with communication and campaigns for more than 20 years for a broad range of both private and public clients in various sectors; food, industry, governmental etc. He has an extensive experience with national election campaigns for the danish parliament for parties like Venstre (The Liberal Party of Denmark), Socialdemokratiet (Social Democratic Party) and SF (Socialist People’s Party). Furthermore he has made international campaigns for EU-groups. Per is a very skilled and experienced art director and copy writer.
Scientific Advisory Board
Stefan Anker (chair)
Professor, MD, PhD
Stefan Anker has 25 years academic research experience in heart failure, cachexia and clinical trials with positions in Imperial College in London as well as University Göttingen,and Charité Berlin. Stefan has been a tenured University-Professor in Germany since 2007, leading a highly active research group, and he is founding Editor-in-Chief of two successful scientific journals (including the Journal of Cachexia, Sarcopenia and Muscle). Stefan was Vice President of the European Society of Cardiology (ESC) from 2016 to 2018, and served on the ESC board from 2012 to 2018. He is serving on the board of the Heart Failure Association (HFA) of the ESC since 2006; and was HFA President from 2012 to 2014. Stefan is the founding president of the International Society on Sarcopenia, Cachexia and Wasting Disorders, a position that he has held since 2008 (see www.cachexia.org). Stefan has been and is a member of over 30 international clinical trial steering committees and is currently chairing or co-chairing 6 trials in phase II/ III/IV. In this context, Stefan has significant experience interacting with regulators in different branches of the FDA and EMA. Stefan has over 900 research papers, 175,000 citations and a h-Index of 162 (Google Scholar). Stefan Anker is a co-founder of Actimed Therapeutics, having previously founded Myotec (later renamed PsiOxus Therapeutics).
PhD, scientific advisor
Michael Mark was the Senior Vice President and Global Head of CardioMetabolic Diseases Research at Boehringer Ingelheim, Germany until his retirement end of 2019. In this role he was responsible for the research and development of innovative treatments for cardiovascular and metabolic diseases including type 2 diabetes mellitus, obesity, NASH and diabetic microvascular complications like eye diseases as well as kidney diseases. Educated as pharmacist Dr Mark is holding a Ph.D. degree in Pharmacology from the University of Tuebingen (Germany). Dr Mark has more than 30 years’ experience in the pharmaceutical industry. Early in his career Dr Mark contributed to the discovery and development of repaglinide (Novonorm®), an approved treatment of type 2 diabetes. He pioneered the discovery of the DPP-4 inhibitor linagliptin (Trajenta®) and was instrumental in the preclinical work for the SGLT2 inhibitor empagliflozin (Jardiance®), both compounds globally marketed. Together with his team he developed a competitive portfolio for cardiometabolic treatment options with various preclinical and several clinical development projects currently ongoing in all of the indications mentioned above. Dr Mark served as Project Coordinator for SUMMIT, an Innovative Medicines Initiative (IMI)-sponsored European consortium of 19 academic centers and 6 major pharmaceutical partners, which aimed and succeeded to identify and characterize novel biomarkers and genetic markers for diabetic complications. Dr Mark authored many peer-reviewed publications and meeting contributions and also various book chapters. In addition he holds numerous patents. Currently Dr Mark is serving on the SAB of the DZD (German Center for Diabetes Research (DZD)) and is acting as a consultant to several pharmaceutical companies.
Annette G. Beck-Sickinger
Prof. Dr., scientific advisor
Annette G. Beck-Sickinger is a professor of biochemistry and bioorganic chemistry at Leipzig University, Germany. Her major research fields include structure-activity relationships of peptide/protein hormones and G protein-coupled receptors. Tightly connected bioorganic synthesis, molecular biology tools, and cell biochemistry are applied to identify novel targets, novel therapeutic concepts and innovative approaches in obesity, epilepsy, cardiovascular diseases and biomaterials. She has been awarded many prizes including the Leonidas Zervas Award of the European Peptide Society (1998), the gold medal of the Max-Bergmann-Kreis (2009), the Albrecht Kossel Award of Biochemistry of the GDCh (2018) and the Du Vigneaud Award of the American Peptide Society (2019). She is a member of the National Academy of Science Leopoldina in Germany and was awarded with the Saxonian Order of Merit in 2017 and the European Chemistry Fellowship in 2019. Since 2020, she is head of the CRC “Structural dynamics of GPCR activation and signaling” funded by the German Science Foundation with 12 Mio €.
MSc, European patent attorney, scientific advisor
Mikkel Bender holds a Master’s degree in Molecular Biology (2003) and is a Certified Danish Patent Agent (2006) and a registered European Patent Attorney (2009). Mikkel Bender has 17 years of experience in private patent practice and is the founding partner at COPA Copenhagen Patents. Mikkel Bender is experienced in drafting and prosecuting patent applications before several patent authorities and jurisdictions especially within the fields of pharmaceuticals, diagnostics, microbiology and molecular biology. In addition, he has extensive experience in opposition and appeal proceedings before the EPO and before the Danish Board of Appeal for Patents and Trademarks as well as litigation proceedings. Mikkel Bender is a founding partner of CopaSeed (2018), which is a start-up supporting initiative formed by Partners at COPA Copenhagen Patents. CopaSeed focus on supporting and aiding start-up companies – especially within Biotech and Pharma – in the initial processes of idea/concept formation, IP generation/landscaping and business plan development. CopaSeed has several start-up companies in the portfolio, with which prosperous collaborations have emerged.